Phaseline

Targets › CLCN2

CLCN2 (Chloride channel protein 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Gastroenterology; next expected readout Oct 2027.

Voltage-gated and osmosensitive chloride channel. Forms a homodimeric channel where each subunit has its own ion conduction pathway. (UniProt, P51788)

Open in Phaseline: the race on CLCN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Third Military Medical UniversityLubiprostone
Chloride channel protein 2 opener
CLCN2Phase 3Slow Transit ConstipationOct 2027

Conditions

Slow Transit Constipation (1)

Modalities

small molecule (1)

Companies

Third Military Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.